[The RAAS and SARS-CoV-2: A riddle to solve]. / El SRAA y el SARS-CoV-2: el acertijo a resolver.
Hipertens Riesgo Vasc
; 37(4): 169-175, 2020.
Article
em Es
| MEDLINE
| ID: mdl-32527699
The first case of COVID-19 was reported on 31 December 2019 in Wuhan, China. Ever since there has been unprecedented and growing interest in learning about all aspects of this new disease. Debate has been generated as to the association between antihypertensive therapy with renin-angiotensin-aldosterone system (RAAS) inhibitors and SARS-CoV-2 infection. While many questions as yet remain unanswered, the aim of this report is to inform health professionals about the current state of knowledge. Because this is an ever-evolving topic, the recommendation is that it be updated as new evidence becomes available. Below, we provide a review of pre-clinical and clinical studies that link coronavirus to the RAAS.
Palavras-chave
Angiotensin receptor blocker; Angiotensin-converting enzyme inhibitors; Antagonistas del receptor de angiotensina II; High blood pressure; Hipertensión arterial; Inhibidores de la enzima convertidora de angiotensina; Renin-angiotensin-aldosterone system; SARS-CoV-2; Sistema renina-angiotensina-aldosterona
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Viral
/
Sistema Renina-Angiotensina
/
Infecções por Coronavirus
/
Pandemias
/
Betacoronavirus
Tipo de estudo:
Etiology_studies
/
Guideline
/
Prognostic_studies
Idioma:
Es
Revista:
Hipertens Riesgo Vasc
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Argentina
País de publicação:
Espanha